NASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free ASND Stock Alerts $124.04 -0.78 (-0.62%) (As of 04:27 PM ET) Add Compare Share Share Today's Range$123.69▼$128.2550-Day Range$124.82▼$153.9752-Week Range$83.75▼$161.00Volume944,375 shsAverage Volume380,315 shsMarket Capitalization$7.22 billionP/E RatioN/ADividend YieldN/APrice Target$173.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Ascendis Pharma A/S alerts: Email Address Ascendis Pharma A/S MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside39.6% Upside$173.88 Price TargetShort InterestBearish6.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.52Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.69) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 starsMedical Sector749th out of 928 stocksPharmaceutical Preparations Industry353rd out of 431 stocks 3.4 Analyst's Opinion Consensus RatingAscendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAscendis Pharma A/S has only been the subject of 4 research reports in the past 90 days.Read more about Ascendis Pharma A/S's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.36% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 2.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASND. Previous Next 2.0 News and Social Media Coverage News SentimentAscendis Pharma A/S has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Ascendis Pharma A/S this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 2 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ascendis Pharma A/S's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.69) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -12.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -12.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ascendis Pharma A/S's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About Ascendis Pharma A/S Stock (NASDAQ:ASND)Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Read More ASND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASND Stock News HeadlinesMay 15 at 2:24 AM | stockhouse.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon(TM) PTH for Adults with HypoparathyroidismMay 14 at 4:22 PM | finance.yahoo.comUPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapyMay 14 at 4:22 PM | finance.yahoo.comUS Equity Markets Close Higher Tuesday as Producer Prices RiseMay 14 at 2:43 PM | reuters.comFDA extends review of Ascendis Pharma's hormone disorder therapyMay 14 at 2:31 PM | globenewswire.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismMay 13 at 8:30 AM | globenewswire.comSignificant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialMay 9, 2024 | globenewswire.comLatest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024May 8, 2024 | seekingalpha.comAn Update On Ascendis Pharma's Path To ProfitabilityMay 6, 2024 | finance.yahoo.comAscendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call TranscriptMay 5, 2024 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) PT Raised to $170.00 at JPMorgan Chase & Co.May 5, 2024 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Stock Rating Reaffirmed by Cantor FitzgeraldMay 5, 2024 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) PT Raised to $262.00May 4, 2024 | finance.yahoo.comAscendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 2, 2024 | investorplace.comASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024May 2, 2024 | globenewswire.comAscendis Pharma Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comAscendis Pharma (spons ADRs) earnings preview: what to expectApril 29, 2024 | msn.comDevelopment dedicated to bioscience, pharma moves forward in ArlingtonApril 29, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday TradingApril 26, 2024 | benzinga.comLooking Into Ascendis Pharma's Recent Short InterestApril 25, 2024 | globenewswire.comAscendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024April 24, 2024 | markets.businessinsider.comUnited Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismApril 24, 2024 | markets.businessinsider.comAscendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic HypoparathyroidismApril 24, 2024 | globenewswire.comUnited Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismApril 12, 2024 | benzinga.comAscendis Pharma's Options Frenzy: What You Need to KnowApril 7, 2024 | seekingalpha.comWeek In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 BillionSee More Headlines Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/15/2024Next Earnings (Estimated)9/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ASND CUSIPN/A CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees879Year FoundedN/APrice Target and Rating Average Stock Price Target$173.88 High Stock Price Target$262.00 Low Stock Price Target$113.00 Potential Upside/Downside+37.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($9.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-521,070,000.00 Net Margins-152.68% Pretax Margin-150.57% Return on Equity-16,574.15% Return on Assets-60.06% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.54 Sales & Book Value Annual Sales$288.08 million Price / Sales25.55 Cash FlowN/A Price / Cash FlowN/A Book Value($4.44) per share Price / Book-28.47Miscellaneous Outstanding Shares58,220,000Free Float34,934,000Market Cap$7.36 billion OptionableOptionable Beta0.54 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jan Moller Mikkelsen (Age 64)President, CEO, Member of Executive Board & Executive Director Mr. Scott T. Smith (Age 50)CFO, Executive VP & Member of Executive Board Ms. Lotte Sonderbjerg (Age 63)Executive VP, Chief Administrative Officer & Member of the Executive Board Mr. Michael Wolff Jensen L.L.M. (Age 53)Executive VP, Chief Legal Officer & Member of the Executive Board Mr. Mads BodenhoffSenior VP of Finance & Principal Accounting OfficerMr. Timothy J. LeeSenior Director of Investor RelationsMr. Flemming Steen Jensen (Age 63)Executive Vice President of Product Supply & Quality Dr. Kennett Sprogoe Ph.D. (Age 45)Executive VP and Head of Research & Product Development Dr. Stina Singel M.D. (Age 50)Ph.D., Executive VP & Head of Clinical Development for Oncology Mr. Joseph Kelly (Age 55)Head of U.S. Commercial of Endocrinology More ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZIntra-Cellular TherapiesNASDAQ:ITCICerevel TherapeuticsNASDAQ:CEREViking TherapeuticsNASDAQ:VKTXLegend BiotechNASDAQ:LEGNView All CompetitorsInstitutional OwnershipAvoro Capital Advisors LLCBought 211,111 shares on 5/15/2024Ownership: 6.813%Price T Rowe Associates Inc. MDBought 336,976 shares on 5/15/2024Ownership: 3.061%PEAK6 Investments LLCSold 500 shares on 5/15/2024Ownership: 0.000%Capital International InvestorsBought 10,044 shares on 5/14/2024Ownership: 3.764%Nan Fung Group Holdings LtdBought 13,600 shares on 5/14/2024Ownership: 0.023%View All Institutional Transactions ASND Stock Analysis - Frequently Asked Questions Should I buy or sell Ascendis Pharma A/S stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ASND shares. View ASND analyst ratings or view top-rated stocks. What is Ascendis Pharma A/S's stock price target for 2024? 8 brokers have issued 1 year price objectives for Ascendis Pharma A/S's stock. Their ASND share price targets range from $113.00 to $262.00. On average, they anticipate the company's share price to reach $173.88 in the next twelve months. This suggests a possible upside of 39.6% from the stock's current price. View analysts price targets for ASND or view top-rated stocks among Wall Street analysts. How have ASND shares performed in 2024? Ascendis Pharma A/S's stock was trading at $125.95 at the start of the year. Since then, ASND shares have decreased by 1.1% and is now trading at $124.54. View the best growth stocks for 2024 here. When is Ascendis Pharma A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 3rd 2024. View our ASND earnings forecast. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($1.47) EPS for the quarter, beating the consensus estimate of ($2.60) by $1.13. The biotechnology company had revenue of $1.31 million for the quarter, compared to analysts' expectations of $1.60 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 16,574.15% and a negative net margin of 152.68%. During the same quarter last year, the business posted ($2.70) earnings per share. What ETFs hold Ascendis Pharma A/S's stock? ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Tema Cardiovascular and Metabolics ETF (HRTS), Virtus LifeSci Biotech Products ETF (BBP), BNY Mellon Innovators ETF (BKIV), Harbor Disruptive Innovation ETF (INNO), American Century Focused Dynamic Growth ETF (FDG) and Fidelity Disruptive Medicine ETF (FMED). What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA). When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Westfield Capital Management Co. LP (7.00%), Avoro Capital Advisors LLC (6.81%), Capital International Investors (3.76%), Price T Rowe Associates Inc. MD (3.06%), TimesSquare Capital Management LLC (0.99%) and Sei Investments Co. (0.59%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASND) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBill Clinton Backing Biden Replacement???The Freeport SocietyHow to Play the AI and Crypto Markets in One SwingWeiss RatingsAmazon's betting big on this unknown AI companyManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.